Method of examining efficacy of therapy with nucleic acid
OwnerKazuko Hirabayashi, Junichi Yanoinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of examining efficacy of treatment with a nucleotide or a nucleoside having antitumor- or antivirus activity in individual patients beforehand, which method is mainly connected to tailor-made therapy, a method of screening for agents potentially having antitumor or antivirus activity, and method of investigating the mechanism of action of an antitumor or antivirus agent in vivo.
Claims14
A method of examining efficacy of treatment with a nucleotide or a nucleoside in a given subject comprising:
- (a) measuring the amount of expression or activity of at least one protein among those each having amino acid sequences of SEQ ID NO:
- 1-4 in a blood or tissue sample previously taken from the subject;
- (b) administering the nucleotide or the nucleoside into a tissue of the subject or a tissue taken from the subject followed by measuring the amount of expression or activity of the same protein as that measured in (a) in blood or treated tissue after 3-48 hours from administration;
- and
- (c) comparing the measurement obtained in step (a) with that obtained in step (b) and evaluating the change in the amount of expression or the activity of the protein.
A method of examining efficacy of treatment with a nucleotide or a nucleoside in a given subject comprising:
- (a) measuring the amount of expression or activity of at least one protein among those each having amino acid sequences of SEQ ID NO:
- 5-30 in a blood or tissue sample previously taken from the subject;
- (b) administering the nucleotide or the nucleoside into a tissue of the subject or a tissue taken from the subject followed by measuring the amount of expression or activity of the same protein as that measured in (a) in blood or treated tissue after 3-48 hours from administration;
- and
- (c) comparing the measurement obtained in step (a) with that obtained in step (b) and evaluating the change in the amount of expression or the activity of the protein.
A method of examining efficacy of treatment with a complex of polyinosinic acid•polycytidylic acid of average chain length between 100 bp and 500 bp with a cationic liposome carrier which comprises as basic essential components 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol and a phospholipid in the ratio of 1:3 to 2:1 (the glycerol derivative:the phospholipid) by weight in a given subject comprising:
- (a) measuring the amount of expression or activity of at least one protein among those each having amino acid sequences of SEQ ID NO:
- 1-4 in a blood or tissue sample previously taken from the subject;
- (b) administering the nucleotide or the nucleoside into a tissue of the subject or a tissue taken from the subject followed by measuring the amount of expression or activity of the same protein as that measured in (a) in blood or treated tissue after 3-48 hours from administration;
- and
- (c) comparing the measurement obtained in step (a) with that obtained in step (b) and evaluating the change in the amount of expression or the activity of the protein.
A method of screening for agents potentially having antitumor or antivirus activity comprising examining a test compound for ability to bind to at least one protein among those each having amino acid sequences of SEQ ID NO:
- 1-4.
A method of screening for agents potentially having antitumor or antivirus activity comprising examining a test compound for ability to bind to at least one protein among those each having amino acid sequences of SEQ ID NO:
- 5-30.
A method of investigating the mechanism of action of an antitumor or antivirus agent in vivo comprising examining the antitumor or antivirus agent for ability to bind to at least one protein among those each having amino acid sequences of SEQ ID NO:
- 1-4.
A method of investigating the mechanism of action of an antitumor or antivirus agent in vivo comprising examining the antitumor or antivirus agent for ability to bind to at least one protein among those each having amino acid sequences of SEQ ID NO:
- 5-30.
Dependencies are inferred from the claim text.